Physician profile
Sidarth Dasari
NPI 1497286421
$137,292.29
in general payments reported to CMS, 2019-2025
44 companies · $39K in 2025
The $39K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86K · 2022: $403 · 2023: $3,713 · 2024: $8,793 · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $18K · Consulting Fee: $7,454 · Travel and Lodging: $2,178 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,230.00 |
| Food and Beverage | $18,216.87 |
| Consulting Fee | $7,454.00 |
| Travel and Lodging | $2,178.47 |
| Education | $110.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $85,396.90 | 2021-2025 | Tysabri, Vumerity, Qalsody |
| Tg Therapeutics, INC. | $29,290.72 | 2023-2025 | |
| Emd Serono, INC. | $5,720.62 | 2022-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $2,846.07 | 2023-2025 | |
| Genentech USA, INC. | $2,095.56 | 2021-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Pfizer INC. | $2,069.94 | 2023-2025 | |
| Abbvie INC. | $1,911.78 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Novartis Pharmaceuticals Corporation | $1,641.81 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $923.73 | 2023-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $682.27 | 2022-2025 | Vyepti |
| Celgene Corporation | $651.37 | 2022-2025 | Zeposia |
| Argenx US, INC. | $445.96 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $419.72 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $353.51 | 2024-2025 | Ingrezza |
| Ucb, INC. | $342.63 | 2023-2025 | Fintepla, Rystiggo |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $340.12 | 2024-2025 | Acthar |
| Amgen INC. | $305.19 | 2022-2025 | Uplizna |
| Sk Life Science, INC. | $243.19 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $210.89 | 2022-2025 | Austedo Xr, Austedo Xr |
| Csl Behring | $169.23 | 2024-2025 | Hizentra |
| Ani Pharmaceuticals, INC. | $151.52 | 2024-2025 | Purified Cortrophin Gel |
| Banner Life Sciences, LLC | $122.57 | 2023-2024 | |
| Grifols USA, LLC | $108.89 | 2023-2025 | Gamunex-C |
| Horizon Therapeutics Plc | $83.45 | 2023 | Uplizna |
| Abbott Laboratories | $74.06 | 2023-2025 | Infinity |
| Neurelis, INC. | $73.15 | 2023-2025 | Valtoco |
| Mdd US Operations, LLC | $67.51 | 2024-2025 | Gocovri |
| Axsome Therapeutics, INC. | $64.86 | 2025 | Symbravo, Sunosi |
| Scilex Pharmaceuticals INC. | $64.17 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $51.87 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $39.34 | 2024 | Wainua |
| Janssen Biotech, INC. | $36.61 | 2025 | |
| Azurity Pharmaceuticals, INC. | $35.76 | 2023-2024 | Horizant, Horizant |
| Catalyst Pharmaceuticals, INC. | $33.70 | 2024-2025 | |
| Tanabe Pharma America, INC. | $32.53 | 2025 | Radicava |
| Life Molecular Imaging LTD | $30.31 | 2024-2025 | Neuraceq |
| Acadia Pharmaceuticals INC | $28.87 | 2025 | Nuplazid |
| Springworks Therapeutics, INC. | $25.99 | 2025 | Gomekli |
| Biohaven Pharmaceutical Holding Company LTD. | $23.61 | 2022 | |
| Vanda Pharmaceuticals INC. | $20.51 | 2025 | Ponvory |
| Merz Pharmaceuticals, LLC | $17.84 | 2025 | Inbrija, Ampyra, Xeomin |
| Inspire Medical Systems, INC. | $15.59 | 2025 | Inspire |
| Genentech, INC. | $14.53 | 2025 | Ocrevus |
| Insightec,INC | $13.84 | 2025 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidarth Dasari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.